1. Home
  2. Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Antisense remains on track to positive clinical trial results

Finfeed Archived Mar 18, 2020

The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.

Get expert stock analysis direct in your inbox

Join Our
Mailing List